NCT03699241View on ClinicalTrials.gov

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

March 21, 2023

Study Completion Date

July 11, 2023

Conditions
HIV Infections
Interventions
BIOLOGICAL

BG505 SOSIP.664 gp140, adjuvanted

Dosage of 30ug, Intramuscular administration

BIOLOGICAL

BG505 SOSIP.664 gp140, adjuvanted

Dosage of 100ug, Intramuscular administration

BIOLOGICAL

BG505 SOSIP.664 gp140, adjuvanted

Dosage of 300ug, Intramuscular administration

BIOLOGICAL

Placebo

Tris-NaCl Diluent

Trial Locations (3)

98109

Fred Hutchinson Cancer Research Center, Seattle

02114

MGH, Boston

Unknown

Kenya AIDS Vaccine Initiative, Nairobi

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Fred Hutchinson Cancer Research Center - Seattle HIV Vaccine Trials Unit

UNKNOWN

collaborator

Kenya AIDS Vaccine Initiative - Institute of Clinical Research (KAVI-ICR)

UNKNOWN

collaborator

Massachusetts General Hospital

OTHER

lead

International AIDS Vaccine Initiative

NETWORK